Our Focus: Two of the Largest Unmet Needs in Eye Care

MICRO-INVASIVE GLAUCOMA SURGERY (MIGS)

40 Global Patents for Surgical Glaucoma

DRY EYE DISEASE

14 Global Patents for Dry Eye Disease
Procedures Represent the Smallest Portion of the US Dry Eye Market Today, but the Largest Growth Opportunity for Tomorrow

US Revenue for Dry Eye Products by Segment

- Procedures 4%
- OTC 25%
- Rx 71%

'16-'22 CAGR
- OTC 4%
- Rx 3%
- Procedures 40%

Market Scope 2017 Dry Eye Products Report
Enabling \textbf{ALL} ECPs to treat Dry Eye Disease
TearCare® Indication for Use

The TearCare® System is indicated for the application of localized heat when the current medical community recommends the application of a warm compress to the eyelids. Such applications would include Meibomian Gland Dysfunction (MGD), Dry Eye, or Blepharitis.
Mindful and Methodical
Dry eye is a multi-factorial disease and patients deserve more than cookie-cutter and shortcut treatments

- Natural-blink design
- Ultra-precise Meibomian gland clearance
- Featuring a first-of-its-kind smart system
Introducing: TearCare®

- Charging Nest
- SmartHub™
- Clearance Assistant™
- SmartLids™
TearCare® During Thermal Delivery and Clearing

Thermal Delivery

Lower Eyelid

Upper Eyelid
Pilot Study Results
TearCare® 6 & 12-Month Pilot Study

Purpose:

• Preliminary Assessment of the Long-Term Safety & Effectiveness of the TearCare® System in the Treatment of the Signs & Symptoms of Dry Eye Disease

• Assess Re-Treatment at 6 months

• Gather data to help design pivotal study

Study Details:

• Single Center: David Badawi, MD

• Prospective, randomized, controlled trial

• 24 Subjects followed for 6 months

  • 12 TearCare subjects

  • 12 Warm Compress subjects (5 minutes daily for 1 month)

• All 12 original TearCare subjects were re-treated at 7 months and followed for another 6 months (13 months total) (re-treatment results not yet published)
**SIGNS: Tear Breakup Time**

- **Mean TBUT in Seconds (SD)**
  - *p<0.0001 (TC compared to WC)
  - **p<0.001 (compared to TC baseline)**

Graph showing the mean TBUT over time for TearCare and Warm Compress treatments.

- **TearCare**
- **Warm Compress**

Retreatment at 7 Months
SYMPTOMS: OSDI

Mean OSDI Score (SD)

Retreatment at 7 Months

p values: TC compared to WC

* P values: TC compared to Baseline

TearCare - Warm Compress

p=0.02
p=0.07
p=0.02
p=0.03
p=0.002
P<0.001
p=0.004
6 Month Pilot Study

- Published in Clinical Ophthalmology, April 2018
- The findings of this pilot study suggest that the TearCare System is a safe and effective treatment option for patients with DED, with the treatment effects persisting for at least 6 months.

6 Month Extension including Re-Treatment

- Manuscript being prepared for publication.
- Re-Treatment with TearCare provided similar therapeutic effect of a similar duration (at least 6 months) as the first treatment.
- Multi-center, randomized controlled trial is warranted to further evaluate the TearCare procedure.
For More Information and Updates: sightsciences.com